Key Facts Surrounding This News Item
- ODT had returned 0.00% year-to-date leading up to today’s news, versus a 0.00% return from the benchmark S&P 500 during the same period.
More Info About Odonate Therapeutics, Inc. (ODT)
Odonate Therapeutics, LLC develops therapeutics to enhance the lives of patients with cancer in the United States. It is developing Tesetaxel, a novel chemotherapy agent that has completed Phase II clinical trials for patients with advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California. View our full ODT ticker page with ratings, news, and more.